© 2022 Annals of Pediatric Cardiology | Published by Wolters Kluwer ‐ Medknow The management of congenital heart disease (CHD) has changed considerably in the recent years. On one side, there has been increased emphasis on earlier corrective surgeries and on palliative or radical repairs of conditions that were previously considered inoperable, whereas, on the other, there have been tremendous advancements in interventional transcatheter techniques, mainly attributable to the advancements in hardware and imaging techniques.

Pediatric interventional cardiology: Breaking new grounds

The new version of the website is designed to be more user-friendly, with the ability to publish and access multimedia content alongside journal articles. The online experience is enriched with article content available in a rich full-text format, along with PDF downloads and a variety of personalization options. The responsive mobile version of the website, made for current-generation smartphones, is easily optimizable based on the users’ device preferences. We are using Wolters–Kluwer’s e-Journals new platform (eJP). Using the eJP’s intuitive editorial tools, we now have the capabilities to build additional content around the articles. We plan to have custom content collections, blogs, podcasts, and standalone-video libraries around the key articles. The new site can be accessed at https://journals.lww.com/ AOPC/Pages/default.aspx. We sincerely hope that the readers like the new website along with its enriched contents.

Annals of Pediatric Cardiology: A new look and a new outlook

Background Transcatheter valves provide a safe and effective alternative to surgery for treating dysfunctional right ventricular outflow tracts (RVOTs). We present our early multicenter experience of percutaneous pulmonary valve implantation (PPVI) using Melody valve (Medtronic Inc., Minneapolis, MN). Methods Patients with stenosed conduits or degenerated bioprosthetic valves in RVOT with combined stenosis and regurgitation were evaluated for suitability of Melody valve implantation. After undergoing an initial structured training, PPVI using Melody transcatheter pulmonary valve (TPV) was guided by an approved proctor. Conduits were serially dilated and prestented with careful coronary interrogation, and bioprosthetic valves were dilated with high-pressure balloons. Clinical and echocardiographic follow-up was performed at 6 monthly intervals. Results Fifteen patients (three females) aged 23.1 ± 9.5 years in NYHA Class II-III underwent Melody TPV implantation in four Indian centers. The underlying anatomy comprised surgically implanted bioprosthetic valves for pulmonary regurgitation (n= 5), conduit repair for pulmonary atresia (n = 4), Rastelli repair (n = 3), truncus (n = 1), and Ross procedure (n = 2). Twelve patients had more than one previous surgery. Doppler gradient decreased from 74.2 ± 21.5 mmHg to 10.2 ± 4.5 mmHg after the PPVI. At a median follow-up of 14 months (1-39 months), all the patients were in NYHA Class I with echocardiographic gradients of 8 ± 5.7 mmHg with no evidence of pulmonary regurgitation. There were no major procedural adverse events or deaths. Conclusions Our early experience shows encouraging results of the PPVI program in India with proctored case selection and meticulous planning. It also confirms the safety and efficacy of Melody TPV for treating dysfunctional RVOT in postoperative patients.

Maulik Parekh

Papers

Early multicenter experience of Melody valve implantation in India